Abstract Aims This post hoc analysis investigates the impact of baseline characteristics on the efficacy and safety of oral semaglutide in a Chinese population with type 2 diabetes. Materials and Methods Chinese participants from the PIONEER 11 and 12 trials with type 2 diabetes aged ≥18 years were randomised to once‐daily oral semaglutide 3, 7, or 14 mg, or placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12). Changes from baseline in HbA 1c and body weight at week 26 were analysed in subgroups according to the following baseline characteristics: age, HbA 1c , body mass index, duration of diabetes, and presence of gastrointestinal disease. Adverse events (AEs) by baseline subgroups were also assessed. Results In total, 390 (PIONEER 11) and 1084 (PIONEER 12) Chinese participants with type 2 diabetes were evaluated. Most baseline characteristics were similar across the two trials in the different subgroups. Overall, greater reductions in HbA 1c and body weight were observed with oral semaglutide versus comparators across the subgroups. A significant difference was observed for change in HbA 1c by baseline HbA 1c subgroups ( p int <0.05), with greater reductions observed in the subgroups with higher baseline HbA 1c . Most AEs were gastrointestinal‐related and mild‐to‐moderate. Conclusions/Interpretation Oral semaglutide reduces HbA 1c and body weight across a range of baseline subgroups in a Chinese population with type 2 diabetes without any unexpected additional safety concerns. These results support the use of oral semaglutide in a broad population in clinical practice.
Ji et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: